Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Sells $1,190,564.07 in Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Marion Mccourt sold 1,137 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the transaction, the executive vice president now owns 12,931 shares of the company’s stock, valued at approximately $13,540,179.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Regeneron Pharmaceuticals Stock Down 1.2 %

Regeneron Pharmaceuticals stock traded down $12.50 during midday trading on Tuesday, hitting $1,044.52. 259,807 shares of the stock were exchanged, compared to its average volume of 477,710. Regeneron Pharmaceuticals, Inc. has a 1 year low of $688.52 and a 1 year high of $1,081.17. The firm has a market cap of $115.10 billion, a P/E ratio of 30.85, a P/E/G ratio of 2.17 and a beta of 0.13. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The company has a 50 day moving average price of $987.40 and a two-hundred day moving average price of $952.81.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The firm had revenue of $3.15 billion for the quarter, compared to analysts’ expectations of $3.19 billion. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Sierra Summit Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth $1,011,000. Dynamic Technology Lab Private Ltd acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth $749,000. Public Employees Retirement Association of Colorado grew its holdings in Regeneron Pharmaceuticals by 16.0% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 16,074 shares of the biopharmaceutical company’s stock worth $14,118,000 after acquiring an additional 2,220 shares in the last quarter. Exchange Traded Concepts LLC grew its holdings in Regeneron Pharmaceuticals by 32.7% during the 4th quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock worth $4,351,000 after acquiring an additional 1,221 shares in the last quarter. Finally, Congress Wealth Management LLC DE acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $271,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. TD Cowen upped their price objective on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Cantor Fitzgerald restated a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. Truist Financial restated a “buy” rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Finally, Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,027.55.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.